Holen Sie sich die Stockscreener-App
10.41
6.29%
-0.71
Schlusskurs vom Vortag:
$11.12
Offen:
$11.15
24-Stunden-Volumen:
2.11M
Relative Volume:
0.61
Marktkapitalisierung:
$2.22B
Einnahmen:
$61.10M
Nettoeinkommen (Verlust:
$-138.36M
KGV:
-7.7111
EPS:
-1.35
Netto-Cashflow:
$-90.59M
1W Leistung:
-7.54%
1M Leistung:
-18.21%
6M Leistung:
-12.88%
1J Leistung:
+30.58%
1-Tages-Spanne:
$10.37
$11.15
1-Wochen-Bereich:
$10.37
$11.88
52-Wochen-Spanne:
$5.80
$16.44
Ocular Therapeutix Inc Stock (OCUL) Company Profile
Firmenname
Ocular Therapeutix Inc
Sektor
Branche
Telefon
781-357-4000
Adresse
15 CROSBY DRIVE, BEDFORD, MA
Vergleichen Sie OCUL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
OCUL
Ocular Therapeutix Inc
|
10.42 | 2.37B | 61.10M | -138.36M | -90.59M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.69 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.62 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
813.59 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.48 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Ocular Therapeutix Inc Stock (OCUL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-15 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-04-08 | Eingeleitet | William Blair | Outperform |
| 2025-03-18 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-03-11 | Eingeleitet | Needham | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-20 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-31 | Fortgesetzt | Piper Sandler | Overweight |
| 2024-02-09 | Eingeleitet | BofA Securities | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-08-10 | Fortgesetzt | Berenberg | Buy |
| 2021-08-10 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2020-12-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2020-12-17 | Eingeleitet | Berenberg | Buy |
| 2020-11-13 | Bestätigt | Raymond James | Strong Buy |
| 2020-08-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-03-03 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2019-05-21 | Herabstufung | Cowen | Outperform → Market Perform |
| 2019-05-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-21 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2018-12-03 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2018-11-15 | Eingeleitet | Raymond James | Strong Buy |
| 2018-09-07 | Eingeleitet | Piper Jaffray | Overweight |
| 2017-10-24 | Eingeleitet | Guggenheim | Buy |
| 2017-07-26 | Eingeleitet | H.C. Wainwright | Buy |
| 2017-07-12 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2017-06-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2017-02-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2016-11-15 | Bestätigt | RBC Capital Mkts | Outperform |
| 2016-08-11 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2016-02-17 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2015-10-23 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2015-08-13 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Ocular Therapeutix Inc Aktie (OCUL) Neueste Nachrichten
Ocular Therapeutix appoints Jason Robins as interim CFO during Notman’s leave By Investing.com - Investing.com India
Ocular Therapeutix appoints Jason Robins as interim CFO during Notman’s leave - Investing.com
Ocular Therapeutix appoints Jason Robins interim CFO - TipRanks
Ocular Therapeutix IncCFO Donald Notman takes medical leaveSEC filing - marketscreener.com
Ocular Therapeutix Names David W. Robinson as Global Chief Commercial Officer - VisionMonday.com
Hiring Retina Veteran as Global CCO Might Change The Case For Investing In Ocular Therapeutix (OCUL) - simplywall.st
Ocular Therapeutix appoints David Robinson as global chief commercial officer - Investing.com Nigeria
Ocular Therapeutix names David Robinson as global CCO - The Pharma Letter
Ocular Therapeutix Appoints David W. Robinson as Global Chief Commercial Officer - citybiz
Ocular Therapeutix hires veteran to lead commercial push for eye drugs; shares up - TradingView — Track All Markets
Piper Sandler Maintains Ocular Therapeutix(OCUL.US) With Buy Rating, Maintains Target Price $31 - 富途资讯
Ocular Therapeutix™ Appoints David W. Robinson as Global Chief Commercial Officer - manilatimes.net
Executive behind EYLEA launch to steer Ocular’s next eye drug AXPAXLI - Stock Titan
How sensitive is Ocular Therapeutix Inc to inflationJuly 2025 Sentiment & Reliable Breakout Stock Forecasts - baoquankhu1.vn
Can Ocular Therapeutix Inc sustain its profitabilityWeekly Investment Report & Safe Entry Momentum Stock Tips - baoquankhu1.vn
Will Ocular Therapeutix Inc benefit from geopolitical trendsEarnings Risk Report & Verified Technical Trade Signals - baoquankhu1.vn
CEO Change: Will Ocular Therapeutix Inc benefit from geopolitical trendsMarket Performance Summary & Expert Verified Movement Alerts - baoquankhu1.vn
Aug Breakouts: Is Ocular Therapeutix Inc gaining market shareJuly 2025 Snapshot & Capital Efficient Trade Techniques - baoquankhu1.vn
Peering Into Ocular Therapeutix Inc's Recent Short Interest - Sahm
Ocular Therapeutix Sees Unusually Large Options Volume (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix (OCUL) Valuation Check After Mixed Recent Returns And AXPAXLI Expectations - Yahoo Finance
Speculation of Sanofi Takeover Sends Ocular’s Stock Soaring - BioSpace
BRIEF—Sanofi reportedly eyeing bid for Ocular Therapeutix - The Pharma Letter
Understanding the Setup: (OCUL) and Scalable Risk - Stock Traders Daily
Ocular Launches, And Then Yo-Yoes, On Rumors Sanofi Is Preparing A Bigger Bid - MSN
Ocular Therapeutix (OCUL) Shares Surge Over 11% - GuruFocus
Ocular Therapeutix, Inc. (OCUL): A Bull Case Theory - Finviz
Sanofi (SNY) Plans Enhanced Offer for Ocular Therapeutix - GuruFocus
Ocular Therapeutix (NASDAQ:OCUL) Shares Gap UpTime to Buy? - MarketBeat
Why Sanofi May Need To Top $2.4 Billion For Ocular Therapeutix (NASDAQ:SNY) - Seeking Alpha
Ocular Therapeutix Target of Unusually High Options Trading (NASDAQ:OCUL) - MarketBeat
Ocular Therapeutix Shares Surge Following Reports Of Stronger Sanofi Bid - Benzinga
Ocular Therapeutix (OCUL) Surges on Potential Sanofi Takeover Bi - GuruFocus
RBC Capital Increases Price Target for OCUL Stock Amid Optimism - StocksToTrade
Ocular Therapeutix shares rise 11.1% - marketscreener.com
Strength Seen in Ocular Therapeutix (OCUL): Can Its 6.1% Jump Turn into More Strength? - Yahoo Finance
RBC Raises Ocular Therapeutix Price Target Amid Positive Outlook - timothysykes.com
Ocular surges on report of Sanofi buyout bid - Seeking Alpha
Why Is Ocular Therapeutix (OCUL) Stock Up Premarket Today? Sanofi Bid Rejection Fuels Rally - Tokenist
Ocular Therapeutics Awaits Wet AMD Trial Data, Stock Up Over 23% - Nasdaq
OCUL Stock Back On Retail Radar With Sanofi Takeover Speculation Resurfacing - Stocktwits
Sanofi readies higher bid for Ocular Therapeutix after initial rejectionreport - Investing.com Canada
Sanofi makes fresh play for Ocular Therapeutix - La Lettre
Is It Time To Reassess Ocular Therapeutix (OCUL) After Recent Share Price Volatility? - simplywall.st
3 Reasons OCUL is Risky and 1 Stock to Buy Instead - Yahoo Finance
VIX Spike: How Ocular Therapeutix Inc stock responds to policy changesEarnings Beat & Free Daily Entry Point Trade Alerts - Bộ Nội Vụ
Take Profit: Is Ocular Therapeutix Inc 0OT stock a buy on weaknessShare Buyback & Smart Swing Trading Alerts - Bộ Nội Vụ
Ocular Therapeutix, Inc. (OCUL) Stock Analysis: A 126% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Ocular Therapeutix outlines AXPAXLI NDA submission timeline with SOL-1 topline data expected Q1 2026 - msn.com
Trading Recap: Why analysts raise outlook for Ocular Therapeutix Inc. (0OT) stock2025 Valuation Update & Detailed Earnings Play Alerts - Bộ Nội Vụ
Ocular Therapeutix (NASDAQ:OCUL) Shares Down 6.5%Here's Why - MarketBeat
Finanzdaten der Ocular Therapeutix Inc-Aktie (OCUL)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.38%
1.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):